BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, February 21, 2026
Home » Topics » Infection » Coronavirus

Coronavirus
Coronavirus RSS Feed RSS

Pills spilling out of prescription bottle

Everest acquires rights to 3CL protease inhibitors to develop antivirals for COVID-19

Jan. 14, 2022
By David Ho
Shanghai-based Everest Medicines Ltd. has won exclusive global rights to a set of viral 3C-like (3CL) protease inhibitors from Singapore's national drug discovery platform, the Experimental Drug Development Centre (EDDC), in a deal worth up to $214.5 million.
Read More
Patrick Doyle, CEO, Kbio Holdings Ltd.
Newco news

BAT follows tobacco rival Philip Morris into biotech, promising faster R&D with Kbio’s plant-based tech

Jan. 14, 2022
By Richard Staines
Following Philip Morris International Inc.’s controversial takeover of respiratory drug firm Vectura plc, British American Tobacco plc (BAT) is also making inroads into medical research with U.K.-based Kbio Holdings Ltd., a biotech focused on plant-based medicine.
Read More

In the clinic for Jan. 14, 2022

Jan. 14, 2022
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Adagene, AI, Ascletis, First Wave, Gritstone, GSK, Imcyse, Oncopeptides, On Target, Redhill, Rhythm, Rubius, Spago, Tempus.
Read More
U.S. flag and White House podium

Biden administration boosts at-home COVID-19 test purchase to 1B

Jan. 13, 2022
By Annette Boyle
In a speech on Jan. 13, President Joe Biden revealed plans to purchase an additional 500 million at-home COVID-19 tests, bringing the total number the administration expects to provide for free to American households to 1 billion. In addition, Biden said the administration would distribute free “high quality masks.” On Wednesday, the administration said it would provide 5 million rapid COVID-19 tests and 5 million lab-based PCR tests to schools each month to support screening testing and test-to-stay programs.
Read More
Pregnancy

Study tracking pregnancies shows increased risk of COVID-19 complications for the unvaccinated

Jan. 13, 2022
By Nuala Moran
LONDON – A population level study tracking every pregnancy in Scotland between the start of the pandemic in March 2020 and the end of October 2021 lays bare the devastating impact of COVID-19 on perinatal mortality.
Read More

Regulatory actions for Jan. 13, 2022

Jan. 13, 2022

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Abivax, Ascendis, Atai, Basilea, Cellular, Denali, Edesa, GSK, Hutchmed, Jeil, Mitsubishi, Novavax, Pharmather, Rockwell, SK, Vir.


Read More

Other news to note for Jan. 13, 2022

Jan. 13, 2022
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Accuredit, Adagio, Advanz, Allecra, Amgen, Atyr, Bridgebio, Bristol Myers Squibb, Can-Fite, Captor, Endo, Halberd, Helmholtz , ITM, Journey Medical, Lysogene, N1, Prellis, Radius Health, Sarepta, Vir, Vyne, Zhittya.
Read More

In the clinic for Jan. 13, 2022

Jan. 13, 2022
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Alar, Arrowhead, Blade, Cyteir, Glaukos, I-Mab, IMV, Mesoblast, Pfizer, Revolution, Vaxxinity, Zai Lab.
Read More
Australian flag on laptop screen with health professional

TGA issues guidance on software requirements for COVID-19 rapid antigen self-tests

Jan. 12, 2022
By Tamra Sami
PERTH, Australia – Australia’s Therapeutic Goods Administration (TGA) released guidance for sponsors and manufacturers on regulatory requirements for software to be used with COVID-19 rapid antigen self-tests that are intended to analyze and interpret tests results.
Read More

In the clinic for Jan. 12, 2022

Jan. 12, 2022
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Abiomed, Caredx, Castle Biosciences, Electrocore, Glaukos, Pictor.
Read More
Previous 1 2 … 142 143 144 145 146 147 148 149 150 … 551 552 Next

Popular Stories

  • Today's news in brief

    BioWorld
  • IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa

    BioWorld Science
    Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
  • 3D illustration of skin layers

    TL1A is overexpressed in hidradenitis suppurativa

    BioWorld Science
    Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
  • Illustration of head with maze that is missing parts

    Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke

    BioWorld Science
    Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
  • Illustration of brain and antibodies

    VST Bio’s VB-001 is neuroprotector after stroke

    BioWorld Science
    At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing